ARDS Aridis Pharmaceuticals Inc.

7.75
+0.23  (+3%)
Previous Close 7.52
Open 7.52
Price To Book 6.35
Market Cap 69,069,759
Shares 8,912,227
Volume 2,015
Short Ratio
Av. Daily Volume 4,740

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 interim data due 1Q 2020 with final data due late-2020.
AR-301 (Salvecin)
Staphylococcus aureus
Phase 2 interim data due 3Q 2019.
AR-105 (Aerucin)
Pseudomonas aeruginosa
Phase 2/3 trial pending AR-105 data.
AR-101 (Aerumab)
Pseudomonas aeruginosa
Phase 1/2 data in healthy subjects due 1Q 2020 and from cystic fibrosis patients in 1Q 2021.
AR-501
Chronic bacterial lung infections in patients with cystic fibrosis (CF)

Latest News

  1. It’s not just Bloom Energy: Half of last year’s Bay Area IPO stocks are underwater
  2. Aridis Pharmaceuticals Announces Second Quarter 2019 Results
  3. Do Insiders Own Lots Of Shares In Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS)?
  4. Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX® Platform Technology
  5. Aridis Pharmaceuticals Receives Orphan Drug Designation From the European Medicines Agency for AR-501
  6. Aridis Pharmaceuticals Receives Orphan Drug Designation for AR-501
  7. Aridis Pharmaceuticals Appoints Dr. Susan Windham-Bannister to Board of Directors
  8. Aridis Pharmaceuticals Announces First Quarter 2019 Results
  9. Will Aridis Pharmaceuticals Continue to Surge Higher?
  10. Aridis Pharmaceuticals (ARDS) Upgraded to Buy: Here's Why
  11. Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update
  12. Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) Has Attractive Fundamentals
  13. Here are the winners and losers from Bay Area's IPO class of 2018
  14. AR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis Patients
  15. This year's Bay Area IPO batch remains up 44% despite market turbulence
  16. Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations
  17. Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics
  18. Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research Highlights Growth, Revenue, and Consolidated Results
  19. Aridis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Corporate Overview
  20. Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in "Intensive Care Medicine" and "The Lancet Respiratory Medicine"